
    
      This was an observational, cross-sectional, retrospective, multicenter study conducted in
      Spain. During the year after authorization of the drug by the European Medicines Agency
      (EMA), patients in the compassionate use program (public sites) and patients treated in
      private sites (no purchase restrictions) who received at least 1 dose of treatment with
      eribulin per approved label at any of the 17 Spanish sites with the highest numbers of
      treated cases during that period (minimum 3 patients/site) were enrolled in this
      observational study. Approximately 112 patients will be enrolled in the study.
    
  